New booster vaccine trial aims to shield japanese teens from three serious diseases
NCT ID NCT07596173
First seen Jun 25, 2026 · Last updated Jul 09, 2026 · Updated 3 times
Summary
This study tests a single booster dose of a combined vaccine against diphtheria, tetanus, and whooping cough (dTpa) in 85 healthy Japanese adolescents aged 11 to 13. Researchers will check if the shot triggers a strong immune response and monitor for side effects one month after vaccination. The goal is to see if this booster can keep teens protected against these infections.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dTpa vaccine (combined reduced-antigen diphtheria, tetanus, and acellular pertussis vaccine)
- What this could lead to
- If successful, this could confirm that a single booster dose of this dTpa vaccine effectively protects Japanese adolescents against diphtheria, tetanus, and pertussis.
- What could go wrong
- This is a small, single-arm study with no comparison group, so results may not apply broadly. The vaccine may cause mild side effects like soreness or fever, and long-term protection is not measured here.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
GSK Investigational Site
RECRUITINGFukuoka, 812-0871, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
GSK Investigational Site
RECRUITINGHokkaido, 004-0052, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
GSK Investigational Site
RECRUITINGHokkaido, 006-0814, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
GSK Investigational Site
RECRUITINGHokkaido, 062-0907, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
GSK Investigational Site
RECRUITINGKumamoto, 862-0924, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
GSK Investigational Site
RECRUITINGMie, 511-0865, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
GSK Investigational Site
RECRUITINGOsaka, 554-0014, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
GSK Investigational Site
RECRUITINGSaitama, 337-0042, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
GSK Investigational Site
RECRUITINGSaitama, 360-0812, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.